Stock BZYR BURZYNSKI RESEARCH INSTITUTE, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Burzynski Research Institute, Inc.

Equities

BZYR

US1231591058

Biotechnology & Medical Research

Market Closed - OTC Markets
Other stock markets
 10:47:19 2024-04-25 am EDT 		5-day change 1st Jan Change
0.0428 USD +2.32% Intraday chart for Burzynski Research Institute, Inc. +21.94% -2.73%
Jan. 16 Burzynski Research Institute, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended November 30, 2023 CI
2023 Burzynski Research Institute, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended August 31, 2023 CI

Valuation

Fiscal Period: February 2018 2019 2020 2021 2022 2023
Capitalization 1 6.572 2.76 1.446 3.812 3.943 4.831
Enterprise Value (EV) 1 6.572 2.76 1.446 3.812 3.94 4.83
P/E ratio -4.08 x -1.69 x -0.88 x -3.17 x -3 x -3.68 x
Yield - - - - - -
Capitalization / Revenue - - - - - -
EV / Revenue - - - - - -
EV / EBITDA -4.08 x - - - - -
EV / FCF 23.1 x 20.2 x 17.5 x -958 x 95.8 x 51.3 x
FCF Yield 4.33% 4.95% 5.71% -0.1% 1.04% 1.95%
Price to Book -61.1 x -14.8 x -9.48 x -83.3 x 3,333 x -353 x
Nbr of stocks (in thousands) 131,448 131,448 131,448 131,448 131,448 131,448
Reference price 2 0.0500 0.0210 0.0110 0.0290 0.0300 0.0368
Announcement Date 5/22/18 5/29/19 5/28/20 5/24/21 5/26/22 5/25/23
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: February 2018 2019 2020 2021 2022 2023
Net sales - - - - - -
EBITDA 1 -1.612 - - - - -
EBIT 1 -1.613 -1.638 -1.635 -1.302 -0.9767 -0.9163
Operating Margin - - - - - -
Earnings before Tax (EBT) 1 -1.612 -1.638 -1.634 -1.204 -0.9767 -0.9163
Net income 1 -1.612 -1.638 -1.634 -1.204 -0.9767 -0.9163
Net margin - - - - - -
EPS 2 -0.0123 -0.0125 -0.0124 -0.009159 -0.009999 -0.009999
Free Cash Flow 1 0.2844 0.1366 0.0825 -0.003978 0.0411 0.0941
FCF margin - - - - - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 5/22/18 5/29/19 5/28/20 5/24/21 5/26/22 5/25/23
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: February 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 0 0 0 0 0 0
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 0.28 0.14 0.08 -0 0.04 0.09
ROE (net income / shareholders' equity) 2,292% 1,113% 964% 1,214% 4,376% 14,637%
ROA (Net income/ Total Assets) -5,084% -4,006% -4,863% -7,820% -21,738% -17,370%
Assets 1 0.0317 0.0409 0.0336 0.0154 0.004493 0.005275
Book Value Per Share 2 -0 -0 -0 -0 0 -0
Cash Flow per Share 2 0 0 0 - 0 0
Capex - - - - - -
Capex / Sales - - - - - -
Announcement Date 5/22/18 5/29/19 5/28/20 5/24/21 5/26/22 5/25/23
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
BURZYNSKI RESEARCH INSTITUTE, INC. Stock Burzynski Research Institute, Inc.
-2.73% 5.62M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+0.67% 42.19B
LONZA GROUP AG Stock Lonza Group AG
+44.30% 40.15B
CELLTRION, INC. Stock Celltrion, Inc.
-6.20% 28.31B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+6.55% 24.63B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.66% 18.2B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.96% 12.01B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-1.57% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+16.03% 10.4B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-4.80% 9.94B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. BZYR Stock
  4. Financials Burzynski Research Institute, Inc.